Table 1_Clinical efficacy and pregnancy outcomes of doxycycline plus medroxyprogesterone acetate therapy for chronic endometritis in women with recurrent reproductive failure: a prospective cohort study.docx

This study evaluated the efficacy and safety of doxycycline plus medroxyprogesterone acetate (MPA) in women with RRF and CE.</p>Material and methods<p>This prospective cohort study included 330 women with RRF and CE diagnosed by CD138 immunohistochemistry. According to the treatment received, patients were classified into the doxycycline group or the doxycycline plus MPA group, with 165 women in each group.

The primary outcome was the histological cure rate of CE after one treatment course. Secondary outcomes included pregnancy rate, live birth rate, pregnancy loss rate, ongoing pregnancy rate, and adverse events. Multivariable Poisson regression with robust variance was used to adjust for potential confounders.</p>Results<p>In the primary efficacy population, CE cure occurred in 117 of 158 patients (74.1%) receiving doxycycline and 130 of 160 (81.2%) receiving doxycycline plus MPA [adjusted risk difference [aRD], 6.1; 95% CI, −3.2–15.4; adjusted risk ratio [aRR], 1.08; 95% CI, 0.96–1.22; P = 0.202].